Company Name, Ticker, Suppliers, else..

Cartesian Therapeutics Inc (NASDAQ: RNAC)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Cartesian Therapeutics Inc 's

Name: Cartesian Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RNAC Sales vs. its Competitors Q1 2026

Comparing the current results to its competitors, Cartesian Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -92.91 %, despite the revenue increase by the most of its competitors of 44.4 %, recorded in the same quarter.

• List of RNAC Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Cartesian Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 324.71 %

<< RNAC Stock Performance Comparisons

<< See the full list of RNAC competitors

Overall company Market Share Q1 2026

Overall company, revenue fell by -92.91 % and company lost market share, to approximately 0 %. << More on RNAC Market Share.

*Market share is calculated based on total revenue.

News about Cartesian Therapeutics Inc Contracts

Revolutionary Gene Therapy Shows Promise in Treating Myasthenia Gravis

July 2, 2024
In a major breakthrough, Cartesian Therapeutics has recently announced positive topline results from their Phase 2b trial of Descartes-08, a promising gene therapy for patients suffering from Myasthenia Gravis (MG). The trial successfully met its primary endpoint, demonstrating statistically significant improvement in patients treated with Descartes-08 compared to those who received a placebo. This article aims to outline the facts and implications of these findings, shedding light on the potential transformation of MG treatment. The Phase 2b Trial:The Phase 2b trial conducted by Cartesian Therapeutics was designed to evaluate the effectiveness of Descartes-08 in patients diagnosed with Myasthenia Gravis. Th...

RNAC's Stock Performance relative to its Competitors

Publicly Traded Peers of Cartesian Therapeutics Inc

Zyversa Therapeutics Inc
Share Performance

-1.00%

Over The Past 5 Days

Zyversa Therapeutics Inc

Profile

Zyversa Therapeutics Inc's business model revolves around developing innovative therapies and treatments for various medical conditions.

More about Zyversa Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.801 mill.	$ - mill.	$ -24.489 mill.

Neurogene Inc
Share Performance

-8.94%

Over The Past 5 Days

Neurogene Inc

Profile

The company develops genetic medicines targeting rare neurological diseases and is currently in clinical stages.

More about Neurogene Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 829.550 mill.	$ - mill.	$ -98.638 mill.

Nektar Therapeutics
Share Performance

-3.42%

Over The Past 5 Days

Nektar Therapeutics

Profile

Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.

More about Nektar Therapeutics's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,393.007 mill.	$ 54.589 mill.	$ -157.127 mill.

Nanoviricides inc
Share Performance

-30.62%

This Quarter

Nanoviricides inc

Profile

Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.

More about Nanoviricides inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 26.688 mill.	$ - mill.	$ -8.091 mill.

Intellia Therapeutics Inc
Share Performance

-10.84%

This Quarter

Intellia Therapeutics Inc

Profile

Intellia Therapeutics Inc is a biotechnology company focused on developing therapies based on CRISPR/Cas9 gene editing technology.

More about Intellia Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,486.457 mill.	$ 66.092 mill.	$ -394.596 mill.

52 more competitors available

Sources: Cartesian Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, August 31, 2026 3:00 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cartesian Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.